Public Health – Prostate–Specific Antigen Testing (Protect Our Prostate Act)

SB 78, the "Protect Our Prostate Act," requires healthcare providers and clinical laboratories to provide standardized information to patients receiving prostate-specific antigen (PSA) tests. It mandates that providers give written preparation instructions before testing, while labs must use FDA-approved tests, calibrate using WHO standards, report results in nanograms per milliliter with reference ranges, and disclose test details to ordering doctors. The law directly affects patients undergoing PSA testing, healthcare providers ordering tests, and clinical laboratories administering the tests. It aims to improve transparency and accuracy of PSA results to help patients understand potential risks like false positives, without changing treatment protocols.